Fruquintinib
Metastasis From Malignant Tumor Of Colon
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Peking University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06199232CT.gov Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment | — | Active Not Recruiting | — | — | — |
NCT05848739CT.gov A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05406206CT.gov Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | — | Unknown | — | — | — |
NCT04322539CT.gov A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03251378CT.gov A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastasis From Malignant Tumor Of Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fruquintinib (this asset) | Peking University | P3 | BBB · 72 |
| Oxaliplatin | Fudan University | P4 | BBB |
| Dexasone | Fudan University | P3 | BB |
| Irinotecan | Jun Huang | P3 | BB |
| Capecitabine | Jun Huang | P3 | BB |
| Cetuximab | Shanghai 6th People's Hospital | P3 | BB |
| Floxuridine | Fudan University | P3 | BB |
| ip-001 | Immunophotonics, Inc. | P2/3 | BB |
| Panitumumab | University of Campania Luigi Vanvitelli | P2 | BB |
+42 more in the Metastasis From Malignant Tumor Of Colon cohort
Other indications for Fruquintinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P4 | BB · 67 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Fruquintinib in Metastasis From Malignant Tumor Of Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fruquintinib-metastasis-from-malignant-tumor-of-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →